The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1

Jolien Fledderus, Byambasuren Vanchin, Marianne G Rots, Guido Krenning*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

10 Citations (Scopus)
52 Downloads (Pure)


Endothelial cell inflammatory activation and dysfunction are key events in the pathophysiology of atherosclerosis, and are associated with an elevated risk of cardiovascular events. Yet, therapies specifically targeting the endothelium and atherosclerosis are lacking. Here, we review how endothelial behaviour affects atherogenesis and pose that the endothelium may be an efficacious cellular target for antiatherogenic therapies. We discuss the contribution of endothelial inflammatory activation and dysfunction to atherogenesis and postulate that the dysregulation of specific epigenetic enzymes, EZH2 and SIRT1, aggravate endothelial dysfunction in a pleiotropic fashion. Moreover, we propose that commercially available drugs are available to clinically explore this postulation.

Original languageEnglish
Article number103
Number of pages21
JournalJournal of personalized medicine
Issue number2
Publication statusPublished - 5-Feb-2021


  • endothelial cell
  • endothelial dysfunction
  • atherosclerosis
  • arteriosclerosis
  • epigenetics
  • EZH2
  • SIRT1

Cite this